List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5212072/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, The, 2008, 372, 216-223.	13.7	1,333
2	Review: Activation patterns of microglia and their identification in the human brain. Neuropathology and Applied Neurobiology, 2013, 39, 3-18.	3.2	792
3	Consequence of AÎ ² immunization on the vasculature of human Alzheimer's disease brain. Brain, 2008, 131, 3299-3310.	7.6	283
4	Neuropathology of Early HIVâ \in I Infection. Brain Pathology, 1996, 6, 1-12.	4.1	266
5	Aβ Species Removal After Aβ ₄₂ Immunization. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1040-1048.	1.7	260
6	Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathologica, 2009, 118, 87-102.	7.7	256
7	Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. European Journal of Neuroscience, 2003, 17, 2147-2155.	2.6	243
8	Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain, 2013, 136, 2677-2696.	7.6	234
9	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer's Research and Therapy, 2010, 2, 1.	6.2	189
10	Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia, 2005, 49, 375-384.	4.9	160
11	Atypical inflammation in the central nervous system in prion disease. Current Opinion in Neurology, 2002, 15, 349-354.	3.6	159
12	Microglial immunophenotype in dementia with Alzheimer's pathology. Journal of Neuroinflammation, 2016, 13, 135.	7.2	159
13	Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease. Brain, 2019, 142, 2113-2126.	7.6	127
14	Neuropathology after active Al̂²42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathologica, 2010, 120, 369-384.	7.7	122
15	Transforming Growth Factor-β1-Mediated Neuroprotection against Excitotoxic Injury <i>in Vivo</i> . Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1174-1182.	4.3	114
16	Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review. Frontiers in Psychiatry, 2017, 8, 238.	2.6	114
17	Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 42.	6.2	99
18	The intrathecal CD163â€haptoglobin–hemoglobin scavenging system in subarachnoid hemorrhage. Journal of Neurochemistry, 2012, 121, 785-792.	3.9	98

#	Article	IF	CITATIONS
19	Molecular Mechanisms of Microglial Motility: Changes in Ageing and Alzheimer's Disease. Cells, 2019, 8, 639.	4.1	93
20	Microglia regulate hippocampal neurogenesis during chronic neurodegeneration. Brain, Behavior, and Immunity, 2016, 55, 179-190.	4.1	90
21	TGFβ1 regulates the inflammatory response during chronic neurodegeneration. Neurobiology of Disease, 2006, 22, 638-650.	4.4	88
22	Microglial alterations in human Alzheimer's disease following Aβ42 immunization. Neuropathology and Applied Neurobiology, 2011, 37, 513-524.	3.2	88
23	Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: ILâ€1β drives amplified responses in primed astrocytes and neuronal network dysfunction. Alzheimer's and Dementia, 2021, 17, 1735-1755.	0.8	87
24	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease. Acta Neuropathologica, 2010, 120, 13-20.	7.7	80
25	Neuropathologically distinct prion strains give rise to similar temporal profiles of behavioral deficits. Neurobiology of Disease, 2005, 18, 258-269.	4.4	74
26	Transforming growth factor beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. Neuropathology and Applied Neurobiology, 2002, 28, 107-119.	3.2	73
27	Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 3.	5.2	69
28	MCP-1 and murine prion disease: Separation of early behavioural dysfunction from overt clinical disease. Neurobiology of Disease, 2005, 20, 283-295.	4.4	62
29	Comparison of Inflammatory and Acute-Phase Responses in the Brain and Peripheral Organs of the ME7 Model of Prion Disease. Journal of Virology, 2005, 79, 5174-5184.	3.4	55
30	TREM2 expression in the human brain: a marker of monocyte recruitment?. Brain Pathology, 2018, 28, 595-602.	4.1	55
31	ISNI 2006 Abstracts. Journal of Neuroimmunology, 2006, 178, 1-271.	2.3	54
32	Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12053.	2.4	53
33	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 88.	5.2	52
34	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. Journal of Alzheimer's Disease, 2021, 83, 5-22.	2.6	52
35	Engineered antibodies: new possibilities for brain PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2848-2858.	6.4	49
36	Heme–Hemopexin Scavenging Is Active in the Brain and Associates With Outcome After Subarachnoid Hemorrhage. Stroke, 2016, 47, 872-876.	2.0	46

#	Article	IF	CITATIONS
37	Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 360-376.	0.8	46
38	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2831-2847.	6.4	45
39	Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. Acta Neuropathologica, 2014, 128, 777-789.	7.7	44
40	Microglial morphology in Alzheimer's disease and after Aβ immunotherapy. Scientific Reports, 2021, 11, 15955.	3.3	43
41	Viral load and neuropathology in the SIV model. Journal of NeuroVirology, 1999, 5, 232-240.	2.1	40
42	Microglia and Astrocyte Function and Communication: What Do We Know in Humans?. Frontiers in Neuroscience, 2022, 16, 824888.	2.8	39
43	Rapid neuroinflammatory changes in human acute intracerebral hemorrhage. Annals of Clinical and Translational Neurology, 2019, 6, 1465-1479.	3.7	36
44	What do we know about the inflammasome in humans?. Brain Pathology, 2017, 27, 192-204.	4.1	35
45	Microglial motility in Alzheimer's disease and after Aβ42 immunotherapy: a human post-mortem study. Acta Neuropathologica Communications, 2019, 7, 174.	5.2	35
46	Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer's disease. Brain, 2021, 144, 1869-1883.	7.6	32
47	Effect of active A <i>β</i> immunotherapy on neurons in human Alzheimer's disease. Journal of Pathology, 2015, 235, 721-730.	4.5	31
48	Virus load and neuropathology in the FIV model. Journal of NeuroVirology, 1996, 2, 377-387.	2.1	30
49	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. Translational Psychiatry, 2020, 10, 267.	4.8	30
50	Investigating Interventions in Alzheimer's Disease with Computer Simulation Models. PLoS ONE, 2013, 8, e73631.	2.5	28
51	Iron Deposition in the Brain After Aneurysmal Subarachnoid Hemorrhage. Stroke, 2022, 53, 1633-1642.	2.0	28
52	Inflammation in dementia with Lewy bodies. Neurobiology of Disease, 2022, 168, 105698.	4.4	26
53	Downregulated apoptosis and autophagy after antiâ€Aβ immunotherapy in Alzheimer's disease. Brain Pathology, 2018, 28, 603-610.	4.1	24
54	Immune environment of the brain in schizophrenia and during the psychotic episode: A human post-mortem study. Brain, Behavior, and Immunity, 2021, 97, 319-327.	4.1	24

#	Article	IF	CITATIONS
55	Metaflammasome components in the human brain: a role in dementia with Alzheimer's pathology?. Brain Pathology, 2017, 27, 266-275.	4.1	22
56	Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization. Acta Neuropathologica Communications, 2019, 7, 141.	5.2	20
57	Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. Neuropathology and Applied Neurobiology, 2020, 46, 623-640.	3.2	20
58	Review: Microglia in motor neuron disease. Neuropathology and Applied Neurobiology, 2021, 47, 179-197.	3.2	20
59	Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain, 2021, 144, 724-745.	7.6	19
60	Innate Immune Anti-Inflammatory Response in Human Spontaneous Intracerebral Hemorrhage. Stroke, 2021, 52, 3613-3623.	2.0	19
61	Immunotherapy for Alzheimer's disease and other dementias. Current Opinion in Neurology, 2005, 18, 720-725.	3.6	17
62	Effect of amyloidâ€Î² (<scp>A</scp> β) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase <scp>(GSK</scp>)â€3β. Neuropathology and Applied Neurobiology, 2015, 41, 445-457.	3.2	17
63	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1219-1226.	1.9	17
64	Progressive multifocal leukoencephalopathy and oligodendroglioma in a monkey co-infected by simian immunodeficiency virus and simian virus 40. Acta Neuropathologica, 2000, 100, 332-336.	7.7	16
65	Innate immunity in Alzheimer's disease: the relevance of animal models?. Journal of Neural Transmission, 2018, 125, 827-846.	2.8	16
66	Haemoglobin Scavenging After Subarachnoid Haemorrhage. Acta Neurochirurgica Supplementum, 2015, 120, 51-54.	1.0	15
67	Neuropil and neuronal changes in hippocampal NADPH-diaphorase histochemistry in the ME7 model of murine prion disease. Neuropathology and Applied Neurobiology, 2004, 30, 292-303.	3.2	11
68	Amyloid-β vaccination for Alzheimer's dementia – Authors' reply. Lancet, The, 2008, 372, 1381-1382.	13.7	11
69	Low susceptibility of resident microglia to simian immunodeficiency virus replication during the early stages of infection. Neuropathology and Applied Neurobiology, 1995, 21, 535-539.	3.2	10
70	Neuroinflammation in ageing and in neurodegenerative disease. Neuropathology and Applied Neurobiology, 2013, 39, 1-2.	3.2	9
71	BRAIN UK: Accessing NHS tissue archives for neuroscience research. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	9
72	A novel method to visualise the threeâ€dimensional organisation of the human cerebral cortical vasculature. Journal of Anatomy, 2018, 232, 1025-1030.	1.5	8

#	Article	IF	CITATIONS
73	PKR modulates abnormal brain signaling in experimental obesity. PLoS ONE, 2018, 13, e0196983.	2.5	8
74	Immunotherapy for Alzheimer's Disease and Other Dementias. Clinical Neuropharmacology, 2006, 29, 22-27.	0.7	7
75	Are we getting to grips with Alzheimer's disease at last?. Brain, 2010, 133, 1297-1299.	7.6	7
76	Microglial contribution to synaptic uptake in the prefrontal cortex in schizophrenia. Neuropathology and Applied Neurobiology, 2021, 47, 346-351.	3.2	7
77	Histopathological correlates of haemorrhagic lesions on <i>ex vivo</i> magnetic resonance imaging in immunized Alzheimer's disease cases. Brain Communications, 2022, 4, fcac021.	3.3	7
78	Novel association between microglia and stem cells in human gliomas: A contributor to tumour proliferation?. Journal of Pathology: Clinical Research, 2015, 1, 67-75.	3.0	6
79	Differential perivascular microglial activation in the deep white matter in vascular dementia developed postâ€stroke. Brain Pathology, 0, , .	4.1	6
80	Rat astrocytic tumour cells are associated with an antiâ€inflammatory microglial phenotype in an organotypic model. Neuropathology and Applied Neurobiology, 2013, 39, 243-255.	3.2	4
81	Effect of antiâ€cancer drugs on microglia in patientâ€derived breast cancer xenografted mouse models. Neuropathology, 2017, 37, 91-93.	1.2	4
82	Combination Therapy in Alzheimer's Disease: Is It Time?. Journal of Alzheimer's Disease, 2022, , 1-17.	2.6	4
83	Amyloid: Vascular and Parenchymal. , 2009, , 355-362.		2
84	Amyloid: Vascular and Parenchymal â~†. , 2017, , .		2
85	Molecular Investigation of the Unfolded Protein Response in Select Human Tauopathies. Journal of Alzheimer's Disease Reports, 2021, 5, 1-15.	2.2	2
86	Miniâ€symposium: Role of the inflammasome in brain pathogenesis: a potential therapeutic target? ― introduction. Brain Pathology, 2017, 27, 190-191.	4.1	1
87	Dissociation between viral load and neuropathology in the SIV model: Key role of glial cells. Journal of Neuroimmunology, 1998, 90, 63.	2.3	0
88	P.1.d.001 Multi-immunostaining for microglial activation in schizophrenia. European Neuropsychopharmacology, 2014, 24, S188-S189.	0.7	0
89	F1-02-03: Microglia heterogeneity in the human Alzheimer's brain. , 2015, 11, P117-P117.		0
90	P3â€106: Acute Systemic Infection and FCΓ Receptors in Alzheimer's Disease: An Immunosuppressive Environment. Alzheimer's and Dementia, 2016, 12, P859.	0.8	0

#	Article	IF	CITATIONS
91	[ECâ€02–02]: THE NEUROINFLAMMATORY PROFILE IN ALZHEIMER's DISEASE: EFFECT OF SYSTEMIC INFECTIC Alzheimer's and Dementia, 2017, 13, P546.	N. _{0.8}	0

92 Synapses and Alzheimers's Disease: Effect of Immunotherapy?. , 2011, , 269-287.

0